Thompson Street Capital Partners Announces the Sale of Analytical Lab Group to Element Materials Technology

ST. LOUIS (July 27, 2020) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that it has completed the sale of Analytical Lab Group (ALG), an industry-leading microbiology and viral lab, to Element Materials Technology (Element), one of the world’s largest providers of materials and product qualification testing, inspection and certification services to the global aerospace, transportation & industrials, connected technologies, energy, and fire & building products sectors.

ALG’s team of 130 scientists and experts operates a number of FDA and EPA compliance focused laboratories in San Francisco, Minneapolis and Boston and has built a strong reputation in the infection prevention market, offering comprehensive testing solutions in the molecular cell biology and virology testing, antimicrobial, pharmaceutical, medical device, biotech and healthcare industries, backed by sound regulatory and scientific expertise. ALG also offers SARS CoV2 antimicrobial and antiviral testing services to its customers in the healthcare, pharmaceutical, consumer products and medical device industries in accordance with EPA guidelines.

TSCP built ALG through a series of acquisitions and growth initiatives, beginning with TSCP acquiring Microbiology Research Associates in Acton, MA in 2015. ALG is led by a strong management team including CEO Alan Roth. Steve Sullivan, a pharmaceutical industry executive, chaired ALG’s board of directors. It is TSCP’s second successful exit in a lab-focused business model in successive funds.

According to Matt Scherrer, Managing Director at TSCP, “ALG has been a ‘buy and build’ platform for TSCP. Via a series of acquisitions that focused on the important trend of antimicrobial and antiviral across a variety of end markets, including pharmaceutical and life sciences, ALG has become a valuable platform in the lab space. We have been pleased to work with a talented management team, led by Alan Roth. ALG’s successful exit is also the third in partnership with laboratory and pharmaceutical services expert, Steve Sullivan, whose steady leadership has been invaluable in many of our life sciences portfolio companies. TSCP’s value creation strategies, focused on revenue growth, have been in full effect at ALG.”

Alan Roth, ALG’s CEO, described further, “Led by our talented team, ALG has become a lab of scale with the right combination of breadth of services and agility to meet clients’ needs. TSCP has been extremely supportive of organic and inorganic investments, including a recent expansion of one of our labs to conduct SARS CoV2 antimicrobial testing. ALG has become a ‘go-to’ lab amongst our customers during TSCP’s ownership period and will continue providing these same, great services.”

Steve Sullivan, outgoing chairman of ALG, described this outcome with TSCP: “This is my third, successful partnership with TSCP where we have added key infrastructure, executed add-on acquisitions, and worked with a strong management team. I’m proud of Alan’s leadership and appreciative of TSCP’s willingness to invest in businesses that sit at the intersection of high potential end markets. In all three investments, it has been rewarding and a delight to work with TSCP.”

ALG was advised by Houlihan Lokey and Sidley Austin’s private equity practice.

###